Analysts Offer Insights on Healthcare Companies: G1 Therapeutics (NASDAQ: GTHX) and Apellis Pharmaceuticals (NASDAQ: APLS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics (GTHXResearch Report) and Apellis Pharmaceuticals (APLSResearch Report) with bullish sentiments.

G1 Therapeutics (GTHX)

In a report issued on October 15, Edward White from H.C. Wainwright reiterated a Buy rating on G1 Therapeutics, with a price target of $82.00. The company’s shares closed last Friday at $13.56.

According to TipRanks.com, White is a 5-star analyst with an average return of 30.3% and a 51.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Currently, the analyst consensus on G1 Therapeutics is a Strong Buy with an average price target of $67.33, a 406.2% upside from current levels. In a report issued on September 30, Raymond James also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Apellis Pharmaceuticals (APLS)

In a report issued on October 15, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Apellis Pharmaceuticals. The company’s shares closed last Friday at $34.81.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.9% and a 46.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.

Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $49.25, implying a 38.8% upside from current levels. In a report issued on October 15, Raymond James also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.